Arctic Therapeutics Announces €26.5M Oversubscribed Series A Financing

· Funding will accelerate the company’s anti-amyloid treatment for rare and common forms of dementia · As well as bringing forward a new class of treatment for inflammatory skin diseases · Sanos Group CEO Jeppe Ragnar Andersen joins the board   REYKJAVIK, ICELAND and PHILADELPHIA, PA – January 22, 2025 – Icelandic drug discovery and development company Arctic Therapeutics (ATx) today announced the successful closing of a €26.5 million oversubscribed Series A financing from a broad syndicate of international investors.   The syndicate includes the EIC Fund, Iceland’s